SEELOS THERAPEUTICS INC's ticker is SEEL and the CUSIP is 81577F109. A total of 84 filers reported holding SEELOS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.24 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,691 | -84.6% | 30,929 | +0.2% | 0.00% | – |
| Q2 2023 | $36,898 | +73.7% | 30,877 | +0.4% | 0.00% | – |
| Q1 2023 | $21,248 | +1.8% | 30,741 | +0.0% | 0.00% | – |
| Q4 2022 | $20,866 | -47.8% | 30,730 | -20.6% | 0.00% | – |
| Q3 2022 | $40,000 | +53.8% | 38,708 | -0.0% | 0.00% | – |
| Q2 2022 | $26,000 | -49.0% | 38,710 | -35.7% | 0.00% | – |
| Q1 2022 | $51,000 | -66.9% | 60,196 | -36.3% | 0.00% | – |
| Q4 2021 | $154,000 | +67.4% | 94,461 | +148.3% | 0.00% | – |
| Q3 2021 | $92,000 | +4500.0% | 38,043 | +8936.3% | 0.00% | – |
| Q1 2021 | $2,000 | 0.0% | 421 | -48.8% | 0.00% | – |
| Q4 2020 | $2,000 | – | 823 | +8.9% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 756 | +5.7% | 0.00% | – |
| Q2 2020 | $1,000 | – | 715 | +252.2% | 0.00% | – |
| Q1 2020 | $0 | – | 203 | +515.2% | 0.00% | – |
| Q4 2019 | $0 | – | 33 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 33 | 0.0% | 0.00% | – |
| Q2 2019 | $0 | – | 33 | 0.0% | 0.00% | – |
| Q1 2019 | $0 | – | 33 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,500,000 | $4,075,000 | 1.71% |
| Connacht Asset Management LP | 498,925 | $813,000 | 0.79% |
| GENDELL JEFFREY L | 2,449,267 | $3,992,000 | 0.32% |
| MANGROVE PARTNERS IM, LLC | 2,133,436 | $3,478,000 | 0.21% |
| Uniplan Investment Counsel, Inc. | 1,550,359 | $2,527,000 | 0.14% |
| Financial Advocates Investment Management | 24,673 | $1,994,000 | 0.13% |
| Connacht Asset Management LP | 72,300 | $118,000 | 0.12% |
| Woodline Partners LP | 4,047,231 | $6,597,000 | 0.09% |
| 1492 Capital Management LLC | 108,286 | $177,000 | 0.09% |
| Ikarian Capital, LLC | 244,171 | $398,000 | 0.06% |